Agomab Therapeutics arrived at its first reporting period as a public company with the answers to the two questions a newly listed biotech is always asked: how much money is in the bank, and when does the next make-or-break data land. The company went public in February at $16.00 per ADS, raised roughly $208 million in gross proceeds, and ended the first half of 2026 with $290 million of cash and cash-based investments (EUR 252.0 million). The balance sheet now funds operations into the first half of 2029 - a runway of close to three years that removes financing pressure from the near-term development agenda. The second half of 2026 is a catalyst-dense window: topline data from the open-label extension portion of the STENOVA study with its lead candidate ontunisertib in fibrostenosing Crohn's disease, and the first efficacy read in patients from the inhaled AGMB-447 program in idiopathic pulmonary fibrosis, are each expected in the coming months.
The financials themselves are the straightforward part of an early-stage story. Agomab has no approved products and no revenue. Research and development expense was $26.4 million (EUR 23.0 million) in the first half, up modestly from $25.3 million (EUR 22.0 million) a year earlier, while general and administrative expense jumped to $14.0 million (EUR 12.2 million) from $7.7 million (EUR 6.7 million) - the increase almost entirely one-off costs tied to the public offering. The net loss widened to $35.6 million (EUR 31.0 million), or $0.92 per share on a reported IFRS basis, from $30.9 million (EUR 26.9 million) in the first half of 2025. There are no non-GAAP measures to reconcile here; every figure is as reported under IFRS in euros, translated at approximately 1.15 to the dollar.
The investment case is not the income statement; it is the pipeline and its timing. Ontunisertib, an oral gut-restricted ALK5 inhibitor, is positioning to be the first approved pharmacologic treatment for fibrostenosing Crohn's disease - a subset of Crohn's with no approved therapy today - with a Phase 2b study, NOV-ERA, set to begin dosing patients in the second half of 2026. AGMB-447, an inhaled ALK5 inhibitor for idiopathic pulmonary fibrosis, has its Phase 2 proof-of-concept initiation also slated for the second half. Around $450 million of the company's roughly $730 million market value sits on two clinical-stage programs, each with a regulatory and competitive position worth tracking closely. The share price fell to a low near $8.75 in mid-June before roughly doubling off that low to a 52-week high near $17.82 in late June, and now trades at about $14.85.